Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-23
2010-02-23
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S121000, C546S272700, C546S273100
Reexamination Certificate
active
07666879
ABSTRACT:
The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.
REFERENCES:
patent: 6492529 (2002-12-01), Kapadia et al.
patent: 7125888 (2006-10-01), Bilodeau et al.
patent: 1 657 242 (2006-05-01), None
patent: WO 99/16755 (1999-04-01), None
patent: WO 01/04115 (2001-01-01), None
patent: WO 03/005999 (2003-01-01), None
patent: WO 03/092595 (2003-11-01), None
patent: WO 2004/052315 (2004-06-01), None
Pargellis, Christopher, Inhibition of p38 MAP Kinase by Utilizing a Novel Allosteric Binding Site, Nature Structural Biology, 2002, 9(4), p. 268-272.
Wu, Zhicai, Design and Synthesis of 3,7-diarylimidazopyridines as Inhibitors if the VEGF-receptor KDR, Bioorganic & Medicinal Chemistry Letters, 14, 2004, p. 909-912.
Barda David Anthony
Burkholder Timothy Paul
Clayton Joshua Ryan
Hao Yan
Henry James Robert
Eli Lilly and Company
McGraw Elizabeth A.
Padmanabhan Sreeni
Pihonak Sarah
Tucker Tina M.
LandOfFree
Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4232041